Calliditas Therapeutics AB (publ) (CALT)
After hours:
| Previous close | 18.27 |
| Open | 17.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.50 - 19.19 |
| 52-week range | 15.25 - 29.30 |
| Volume | |
| Avg. volume | 7,422 |
| Market cap | 494.388M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.76 |
PR NewswireCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.
ZacksNovartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
PR NewswireCalliditas Therapeutics to Attend Conferences in April
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
